Immunic, inc. enrolls first patient in its phase 2 calliper trial of imu-838 in progressive multiple sclerosis

New york, sept. 30, 2021 /prnewswire/ -- immunic, inc. (nasdaq: imux), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, today announced enrollment of the first patient in its phase 2 calliper trial of lead asset imu-838, the company's selective oral dhodh inhibitor, in patients with progressive multiple sclerosis (pms).
IMUX Ratings Summary
IMUX Quant Ranking